GVAX myeloma vaccine(Cell Genesys)(GVAX myeloma vaccine(Cell Genesys)) - 在研适应症：多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

治疗性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [1]

在研适应症

多发性骨髓瘤

非在研适应症-

原研机构

Cell Genesys, Inc.

在研机构

Aduro BioTech, Inc.

非在研机构

Cell Genesys, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 GVAX myeloma vaccine(Cell Genesys) 相关的临床试验

NCT03376477 / Active, not recruiting临床2期IIT

A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).

开始日期2019-09-23

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

NCT00116441 / Completed临床1/2期

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

开始日期2000-10-01

申办/合作机构

Cell Genesys, Inc.

100 项与 GVAX myeloma vaccine(Cell Genesys) 相关的临床结果

登录后查看更多信息

100 项与 GVAX myeloma vaccine(Cell Genesys) 相关的转化医学

登录后查看更多信息

100 项与 GVAX myeloma vaccine(Cell Genesys) 相关的专利（医药）

登录后查看更多信息

100 项与 GVAX myeloma vaccine(Cell Genesys) 相关的药物交易

登录后查看更多信息